media – Page 480 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Human Hepatitis B virus traces found in the Bronze Age by Researchers

Researchers from South Ural State University (SUSU) found that man has been suffering from Hepatitis B since the Bronze Age with the help of viral traces in the genomes of ancient people. To understand how some of the ancient diseases spread and to find out how they might behave in the future, an international collaboration between researchers had been analyzing DNA of the relics of ancient people found in areas from Mongolia to Europe for several years.
- Source: News Medical
- 868
- July 16, 2018
hepatitis Researches
Biontech and Genevant Sciences Join Hands to Roll Out Rare Disease Drugs

In a joint venture, German biopharmaceutical firm BioNTech and Genevant Sciences, a genetic disorder therapeutics maker plan to develop mRNA therapy programmes targeting rare diseases with severely deficient medical attention.
- Source: Pharmaceutical Technology
- 749
- July 16, 2018
biotech Company Insight rare diseases
FDA backs GSK’s Tafenoquine for Malaria Cure

Sanction of a single 300mg dose of GlaxoSmithKline’s tafenoquine in patients 16 years and above for the "radical cure" of malaria was advocated by an FDA advisory committee on finding significant evidence for its efficacy and safety.
- Source: MedPageToday
- 4,422
- July 16, 2018
FDA GSK malaria New Approvals
What is Drug Induced Hepatitis?

The condition is termed as toxic hepatitis, where the exposure to toxins leads to liver inflammation. These toxins can be the result of an overdose of certain medicines.
- Source: Stanford Healthcare
- 692
- July 16, 2018
hepatitis pharmaceutical drugs Researches
That Tingling in Your Leg could be a Worm in Your Spine

Dr. Lionel Piroth and Dr. Marine Jacquier from the Centre Hospitalier Universitaire in Dijon reported in the New England Journal of Medicine, “A 35-year-old French woman presented to the emergency department with weakness, a feeling of electric shocks in both legs, and repeated falls; She reported that the symptoms had been progressing, and she noted that she had had difficulty riding her horse for the preceding three months.”
- Source: NBC News
- 714
- July 16, 2018
Parasite Researches Tape worm
Novartis Shuts Down Its Antimicrobial Research

Despite the looming crises, Novartis will be shutting down antimicrobial research at its Novartis Institutes for Biomedical Research campus in Emeryville, California. There will be a loss of 140 jobs and the current projects will be put up for sale. This company was working on phase 2 clinical trial of LYS228 against complicated urinary tract infections and complicated intra-abdominal infections. The work on anti-dengue drugs and anti-malaria drugs (KAF156 and KAE609) were already in pipeline.
- Source: Fierce Biotech
- 732
- July 16, 2018
AMR antibiotic resistance Company Insight
Robotic Surgery – Effective as Traditional Open Surgery Via RAZOR Trial

The US-based RAZOR (Randomised Open versus Robotic Cystectomy) trial revealed that robotic surgery is equally effective as traditional open surgery in order to treat bladder cancer. The study was funded by the National Cancer Institute and the discovery was published in the Lancet.
- Source: The Verge
- 1,927
- July 16, 2018
medical device Researches robotic surgery
FDA Clearance for Echonous Vein Ultrasound

EchoNous announced that it has been granted FDA 510(k) clearance for its EchoNous Vein ultrasound device which could improve peripheral IV catheter placements. This system could provide real-time clear mages of superficial and deeper veins.
- Source: The Verge
- 5,603
- July 16, 2018
FDA medical device New Approvals ultrasound
FDA Clears First Autonomous AI Diagnostic System Rolled out by University of Iowa Healthcare

The U.S. Food and Drug Administration approved the first autonomous artificial intelligence diagnostic system, IDx-DR and the University of Iowa Healthcare has become the first healthcare organization to implement it.
- Source: HealthcareIT News
- 943
- July 15, 2018
AI digital health New Approvals
Dual Therapy of Ibrutinib Plus Venetoclax Improves Results in MCL

Ibrutinib plus venetoclax (ABT-199) improves outcomes over standard therapy in patients with mantle-cell lymphoma (MCL) and a poor prognosis reports a new research in the New England Journal of Medicine.
- Source: MDLinx
- 747
- July 14, 2018
cancer mantle cell lymphoma Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.